Free Trial

CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) Short Interest Up 312.5% in July

CochLear logo with Medical background

Key Points

  • CochLear Ltd. experienced a staggering 312.5% increase in short interest during July, rising from 800 shares on June 30th to 3,300 shares by July 15th.
  • Despite this increase in short interest, CochLear's stock decreased by 1.8% to $100.79 during recent trading, with a small volume of 807 shares exchanged.
  • In a positive outlook, UBS Group upgraded CochLear's rating from "hold" to "strong-buy", indicating expected growth for the company.
  • Looking to export and analyze CochLear data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY - Get Free Report) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 3,300 shares, agrowthof312.5% from the June 30th total of 800 shares. Based on an average daily volume of 3,700 shares, the short-interest ratio is presently 0.9 days. Based on an average daily volume of 3,700 shares, the short-interest ratio is presently 0.9 days.

CochLear Stock Performance

Shares of CHEOY traded up $2.48 during trading on Thursday, reaching $104.23. The company's stock had a trading volume of 263 shares, compared to its average volume of 11,864. The company has a fifty day moving average of $96.11 and a two-hundred day moving average of $90.16. CochLear has a twelve month low of $74.76 and a twelve month high of $115.85.

Analysts Set New Price Targets

Separately, UBS Group upgraded shares of CochLear from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 18th.

View Our Latest Research Report on CochLear

CochLear Company Profile

(Get Free Report)

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

Recommended Stories

Should You Invest $1,000 in CochLear Right Now?

Before you consider CochLear, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CochLear wasn't on the list.

While CochLear currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines